Vimarsana
Biggest News Aggregation in the World

Controlled Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Controlled Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Controlled Trials Today - Breaking & Trending Today

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis - Vimarsana News

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

Objective To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs. Design Systematic review and meta-analysis. Data sources Five electronic databases of published literature (Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index and Conference Proceedings Citation Index, and PsycInfo) and four databases of unpublished and international literature (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, ProQuest Dissertations and Theses Global, and PsycEXTRA), and handsearching of reference l...

Source: bmj.com
Catheter Ablation for AFib Shows Little to No Benefit in HFpEF, Despite Positive Effect in HFrEF - Vimarsana News

Catheter Ablation for AFib Shows Little to No Benefit in HFpEF, Despite Positive Effect in HFrEF

A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.

Statins slightly up diabetes risk but cardiovascular benefits remain, finds study - Vimarsana News

Statins slightly up diabetes risk but cardiovascular benefits remain, finds study

Statin therapy modestly increases diabetes diagnoses but offers substantial cardiovascular benefits, outweighing the slight rise in glycemia, especially in those near diabetes diagnostic thresholds.

Intravenous Thrombolysis and Direct Oral Anticoagulant vs Non-DOAC in Stroke - Vimarsana News

Intravenous Thrombolysis and Direct Oral Anticoagulant vs Non-DOAC in Stroke

In patients with DOAC use within 48 hours of a stroke, intravenous thrombolysis does not increase risk for hemorrhagic complications.

Intravenous Thrombolysis and Direct Oral Anticoagulant vs Non-DOAC in Stroke - Vimarsana News

Intravenous Thrombolysis and Direct Oral Anticoagulant vs Non-DOAC in Stroke

In patients with DOAC use within 48 hours of a stroke, intravenous thrombolysis does not increase risk for hemorrhagic complications.